文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺立体定向体部放疗联合磁共振成像识别病灶局灶加量后的毒性与患者报告生活质量结局:一项2期试验结果

Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-05-12

这项前瞻性2期试验纳入低或中危前列腺癌患者,前列腺接受40 Gy分5次隔日照射,MRI识别的高疾病负荷区域同步加量至42.5至45 Gy,邻近危及器官区域限制在36.25 Gy(n=100);无MRI病灶者接受37.5 Gy无局灶加量(n=14)。中位随访42个月,未观察到急性或晚期3级及以上胃肠道毒性,1例出现晚期3级泌尿生殖毒性;局灶加量组24个月累积晚期2级及以上泌尿生殖和胃肠道毒性分别为13%和5%,患者报告结局较基线无显著长期变化。

要点

  • 前列腺SBRT 40 Gy分5次联合局灶加量至45 Gy耐受良好,未观察到3级及以上胃肠道毒性。
  • 局灶加量组24个月累积晚期2级及以上泌尿生殖和胃肠道毒性分别为13%和5%。
  • 患者报告 urinary、肠道、激素和性功能生活质量评分较治疗前基线无显著长期变化。

核心结论

  • 前列腺SBRT 40 Gy联合同步局灶加量至45 Gy耐受良好,急性和晚期2级及以上胃肠道及泌尿生殖毒性发生率与其他无前列腺内加量的SBRT方案相似。
  • 患者报告的泌尿、肠道或性功能结局较治疗前基线无显著长期变化。

研究设计与样本

  • 前瞻性2期试验,纳入低或中危前列腺癌患者(Gleason评分≤7、前列腺特异性抗原≤20、T分期≤2b)。
  • 前列腺处方40 Gy分5次隔日照射,MRI识别的前列腺影像报告和数据系统4或5分病灶同步加量至42.5至45 Gy,与危及器官重叠区域(距尿道、直肠和膀胱2 mm以内)限制在36.25 Gy(n=100)。
  • 无治疗前MRI或无MRI识别病灶的患者接受37.5 Gy无局灶加量(n=14)。
  • 2015年至2022年共纳入114例患者,中位随访42个月。

主要发现

  • 未观察到急性或晚期3级及以上胃肠道毒性。
  • 1例患者在16个月时出现晚期3级泌尿生殖毒性。
  • 局灶加量组(n=100)急性2级泌尿生殖和胃肠道毒性发生率分别为38%和4%。
  • 局灶加量组24个月累积晚期2级及以上泌尿生殖和胃肠道毒性分别为13%和5%。
  • 患者报告结局显示治疗后泌尿、肠道、激素或性功能生活质量评分较基线无显著长期变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this prospective phase 2 trial, we investigated the toxicity and patient-reported quality-of-life outcomes in patients treated with stereotactic body radiation therapy (SBRT) to the prostate gland and a simultaneous focal boost to magnetic resonance imaging (MRI)-identified intraprostatic lesions while also de-escalating dose to the adjacent organs at risk. METHODS AND MATERIALS: Eligible patients included low- or intermediate-risk prostate cancer (Gleason score ≤7, prostate specific antigen ≤20, T stage ≤2b). SBRT was prescribed to 40 Gy in 5 fractions delivered every other day to the prostate, with any areas of high disease burden (MRI-identified prostate imaging reporting and data system 4 or 5 lesions) simultaneously escalated to 42.5 to 45 Gy and areas overlapping organs at risk (within 2 mm of urethra, rectum, and bladder) constrained to 36.25 Gy (n = 100). Patients without a pretreatment MRI or without MRI-identified lesions were treated to dose of 37.5 Gy with no focal boost (n = 14). RESULTS: From 2015 to 2022, a total of 114 patients were enrolled with a median follow-up of 42 months. No acute or late grade 3+ gastrointestinal (GI) toxicity was observed. One patient developed late grade 3 genitourinary (GU) toxicity at 16 months. In patients treated with focal boost (n = 100), acute grade 2 GU and GI toxicity was seen in 38% and 4% of patients, respectively. Cumulative late grade 2+ GU and GI toxicities at 24 months were 13% and 5% respectively. Patient-reported outcomes showed no significant long-term change from baseline in urinary, bowel, hormonal, or sexual quality-of-life scores after treatment. CONCLUSIONS: SBRT to a dose of 40 Gy to the prostate gland with a simultaneous focal boost up to 45 Gy is well tolerated with similar rates of acute and late grade 2+ GI and GU toxicity as seen in other SBRT regimens without intraprostatic boost. Moreover, no significant long-term changes were seen in patient-reported urinary, bowel, or sexual outcomes from pretreatment baseline.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Morris BA, Holmes EE, Anger NJ, et al. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37179035. doi:10.1016/j.ijrobp.2023.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。